PND2 SAFETY AND IMMUNOGENICITY OF REBIF® NEW FORMULATION (RNF) A NEW SUBCUTANEOUS FORMULATION OF INTERFERON BETA-1A 44 MCG THREE TIMES WEEKLY: 1-YEAR RESULTS OF A PHASE IIIB STUDY IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS

✍ Scribed by J Simsarian; A AL-Sabbagh; R Bennett; B Stubinski; G Pardo

• Book ID: 118608364
• Publisher: John Wiley and Sons
• Year: 2007
• Tongue: English
• Weight: 68 KB
• Volume: 10
• Category: Article
• ISSN: 1098-3015
• DOI: 10.1016/s1098-3015(10)68801-8